“Growth of Gene Therapies”
One specific trend driving the growth of the Advanced Therapy Medicinal Products (ATMP) market is the increasing focus on gene therapies. These therapies aim to treat genetic disorders by modifying or replacing faulty genes, Zolgensma, a gene therapy for spinal muscular atrophy (SMA) treatment, which has shown significant success in treating this rare and life-threatening condition. The growing pipeline of gene therapies, backed by advancements in CRISPR and viral vector technology, is fueling market expansion. Regulatory bodies such as the FDA are also providing accelerated approvals, further boosting market growth. This trend is expected to continue as novel therapies emerge for genetic conditions and rare diseases.
